2331 related articles for article (PubMed ID: 32087558)
1. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
5. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
6. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review.
Dong J; Yuan L; Hu C; Cheng X; Qin JJ
Pharmacol Ther; 2023 Sep; 249():108488. PubMed ID: 37442207
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.
Dong J; Qin Z; Zhang WD; Cheng G; Yehuda AG; Ashby CR; Chen ZS; Cheng XD; Qin JJ
Drug Resist Updat; 2020 Mar; 49():100681. PubMed ID: 32014648
[TBL] [Abstract][Full Text] [Related]
10. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
11. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
Choi YH; Yu AM
Curr Pharm Des; 2014; 20(5):793-807. PubMed ID: 23688078
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Traditional Chinese Medicine on P-Glycoprotein-Mediated Multidrug Resistance and Approaches for Studying the Herb-P-Glycoprotein Interactions.
Cao Y; Shi Y; Cai Y; Hong Z; Chai Y
Drug Metab Dispos; 2020 Oct; 48(10):972-979. PubMed ID: 32816867
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Wei G; Yang G; Wei B; Wang Y; Zhou S
Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modeling Strategies of Cancer Multidrug Resistance.
Yalcin-Ozkat G
Drug Resist Updat; 2021 Dec; 59():100789. PubMed ID: 34973929
[TBL] [Abstract][Full Text] [Related]
16. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein inhibition: the past, the present and the future.
Darby RA; Callaghan R; McMahon RM
Curr Drug Metab; 2011 Oct; 12(8):722-31. PubMed ID: 21434857
[TBL] [Abstract][Full Text] [Related]
18. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.
Borowski E; Bontemps-Gracz MM; Piwkowska A
Acta Biochim Pol; 2005; 52(3):609-27. PubMed ID: 16175236
[TBL] [Abstract][Full Text] [Related]
19. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Karthikeyan S; Hoti SL
Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
[TBL] [Abstract][Full Text] [Related]
20. Potential of Natural-Based Anticancer Compounds for P-Glycoprotein Inhibition.
Dinić J; Podolski-Renić A; Jeremić M; Pešić M
Curr Pharm Des; 2018; 24(36):4334-4354. PubMed ID: 30648503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
